Peptide blend of KPV, GHK-Cu, BPC-157, and TB-500, studied for tissue repair, gut, skin, and recovery.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on KLOW. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
Adds KPV (anti-inflammatory) to the GHK-Cu/BPC-157/TB-500 repair blend; studied for tissue repair, gut, skin, and recovery.
KLOW combines four peptides, GHK-Cu for skin and connective tissue, KPV for anti-inflammatory signaling via NF-κB inhibition, BPC-157 for soft-tissue repair, and TB-500 for cell migration and tissue healing, into a single injectable blend, though the combination has never been studied together in a published trial.
The most commonly reported effects are mild injection-site redness or swelling and a possible faint blue-green skin tint from GHK-Cu's copper, with less common reports of headache, fatigue, and vivid dreams, though no controlled safety study of the blend exists.
People with active or recent cancer, copper metabolism disorders, pregnancy or breastfeeding, WADA-tested athletes, and those on anticoagulants are commonly cited as groups who should not use KLOW.
CBC with differential (baseline); Comprehensive metabolic panel (CMP) (baseline); CRP (follow-up); ESR (optional); Copper and ceruloplasmin (optional, for repeated high-exposure GHK-Cu use). [Source: peptidedosingprotocols.com]
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for KLOW or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Commonly, a once-daily subcutaneous injection is used, with a typical cycle of 4-6 weeks on and 2-4 weeks off. | not stated | not stated | Peptide Dosing Protocols stackWhat it saysHide(secondary reference; provider confirmation required). |
| ~6.0 mg total blend per day (22.5 units / 0.225 mL at 3.0 mL reconstitution) at maintenance phase; titration starts at ~2.0 mg total blend (7.5 units) and steps up to ~4.0 mg (15 units) then ~6.0 mg (22.5 units) | Once dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4 weeks off; Maximum extension: up to 16 weeks on, 4+ weeks off (no safety data supports continuous use beyond 12 weeks) | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
KLOW is a research-context name for a four-peptide blend that combines GHK-Cu, KPV, BPC-157, and TB-500 in a single vial. The standard format is an 80 mg vial split as 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, and 10 mg TB-500. KLOW is not an FDA-approved treatment and no published clinical trial has evaluated the four-peptide combination together.
Community discussion of KLOW most often centers on tissue-repair research, skin/connective-tissue remodeling, recovery research, and anti-inflammatory research. These are research-context interests, not validated clinical outcomes. Direct human evidence for the KLOW combination does not exist.
Most community protocols reconstitute the 80 mg vial with 3.0 mL bacteriostatic water (about 26.7 mg/mL total blend) and use once-daily subcutaneous injections starting at small volumes. Common research-context daily total-blend amounts range from about 250 mcg total per component up to about 750 mcg per component during a peak phase. None of these are dose recommendations.
Check 80 mg in 3 mL in the calculator →GLOW is a three-peptide blend with GHK-Cu, BPC-157, and TB-500. KLOW adds a fourth peptide, KPV. The KPV component is what distinguishes KLOW — its research focus is on anti-inflammatory signaling (NF-κB inhibition, PepT1-mediated transport in gut models). When chronic inflammation is part of the research interest, KLOW is the more common choice; otherwise GLOW covers the same regenerative components.
Community-derived cycle structures most often run 4-6 weeks on followed by 2-4 weeks off. Some protocols extend to 8-12 weeks with longer off periods. The off period is mainly there to address copper-accumulation concern from the GHK-Cu component, which makes up 62.5% of the blend.
The most common research-context approach is to add 3.0 mL of bacteriostatic water to the 80 mg KLOW vial. This produces about 26.7 mg/mL total blend. The mix is swirled gently — never shaken — and stored refrigerated at 35.6-46.4 F (2-8 C). A peptide reconstitution calculator is the safest way to confirm draw volumes for a specific vial size.
Check 80 mg in 3 mL in the calculator →No. As of June 2026, none of the four peptides in KLOW are FDA-approved for the indications discussed in the research community. BPC-157 and TB-500 are also listed by WADA under category S0 (Unapproved Substances) and are prohibited in tested sport.
Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited).
The reference sections above are imported from our compound knowledge base, which classes the evidence for KLOW as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide blend of GHK-Cu, BPC-157, and TB-500, studied for skin quality, tissue repair, and recovery.
LL-37 is the only known human cathelicidin-derived peptide (37 amino acids), studied in antimicrobial and innate-immunity research models.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
Thymosin alpha-1 is a 28-amino-acid synthetic peptide identical to the endogenous thymic peptide, studied in immune-modulation research models.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.